A Plus Biotechnology Co., Ltd.
A Plus Biotechnology Co., Ltd. engages in the manufacturing and wholesale of orthopedic and other medical devices. The company offers products for chest, shoulder, spine, elbow, wrist and hand, pelvic and hip, knee, foot and ankle, osteotomy, pediatric and ESF, biologics. It also provides technical support services and labor services. A Plus Biotechnology Co., Ltd. is based in New Taipei City, Ta… Read more
A Plus Biotechnology Co., Ltd. - Asset Resilience Ratio
A Plus Biotechnology Co., Ltd. (6918) has an Asset Resilience Ratio of 6.87% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how A Plus Biotechnology Co., Ltd.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down A Plus Biotechnology Co., Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$105.00 Million | 6.87% |
| Total Liquid Assets | NT$105.00 Million | 6.87% |
Asset Resilience Insights
- Limited Liquidity: A Plus Biotechnology Co., Ltd. maintains only 6.87% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
A Plus Biotechnology Co., Ltd. Industry Peers by Asset Resilience Ratio
Compare A Plus Biotechnology Co., Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
FluroTech Ltd
OTCQB:FLURF |
Medical Devices | 0.00% |
|
DRGEM Corporation
KQ:263690 |
Medical Devices | 0.50% |
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022 |
Medical Devices | 0.01% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.26% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 7.79% |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932 |
Medical Devices | 6.64% |
|
Shinhung
KO:004080 |
Medical Devices | 4.17% |
|
UMediC Group Berhad
KLSE:0256 |
Medical Devices | 1.48% |
Annual Asset Resilience Ratio for A Plus Biotechnology Co., Ltd. (2021–2024)
The table below shows the annual Asset Resilience Ratio data for A Plus Biotechnology Co., Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.63% | NT$31.00 Million | NT$1.18 Billion | +2.54pp |
| 2023-12-31 | 0.09% | NT$1.00 Million | NT$1.07 Billion | +0.01pp |
| 2022-12-31 | 0.09% | NT$1.00 Million | NT$1.17 Billion | +0.00pp |
| 2021-12-31 | 0.08% | NT$1.00 Million | NT$1.21 Billion | -- |